Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The merger targets migraine prevention through two lead programs: MT-001 (anti-PACAP monoclonal antibody) and MT-002 (anti-CGRP x PACAP bispecific antibody),…
Mentari Therapeutics and InMed Pharmaceuticals announced a merger wherein InMed shareholders would own approximately 1.51% of the combined entity. The deal was…
Plaintiff firm Brodsky & Smith announced an investigation into whether the InMed board breached fiduciary duties in the proposed Mentari merger (fair process /…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
InMed Pharmaceuticals entered an all-stock definitive merger agreement with Mentari Therapeutics, a private migraine biotech. Combined company will operate as Mentari Therapeutics with concurrent oversubscribed $290 million private placement led by Fairmount with Commodore, Deep Track, Janus Henderson, a16z Bio + Health, Venrock, Wellington, TCGX, Blackstone and others. First-in-human filings expected mid-2026 (MT-001) and Q1 2027 (MT-002).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| InMed Pharmaceuticals Inc. / Mentari Therapeutics, Inc. (this deal) | 2026 | $290M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 2026 deals · Neurology deals